Beta Finch - Thermo Fisher - TMO - EN copertina

Beta Finch - Thermo Fisher - TMO - EN

Beta Finch - Thermo Fisher - TMO - EN

Di: Beta Finch
Ascolta gratuitamente

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.
AI-powered earnings call analysis for Thermo Fisher Scientific (TMO). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch Economia Finanza personale
Episodi
  • Thermo Fisher Scientific Q3 2026 Earnings Analysis

    Thermo Fisher Scientific Q3 2026 Earnings Analysis
    Oct 21 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Thermo Fisher Scientific's third quarter 2026 results — and Jordan, this is a good one.

    **JORDAN:** Oh, it's a good one. Beat and raise, strong end markets, tariff refunds... there's a lot to unpack.

    **ALEX:** There really is. But before we get into it — quick reminder for everyone listening: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Important stuff, let's get into the numbers.

    **ALEX:** Okay, so headline numbers first. Revenue came in at $12.14 billion, up 9% year-over-year. Adjusted EPS grew 15% to $6.68 per share. And adjusted operating margin expanded 120 basis points to 24.5%.

    **JORDAN:** And here's the thing — this wasn't just "in line" or a small beat. CFO Jim Meyer said Q3 revenue came in more than $200 million ahead of their prior guidance, and EPS beat by $0.26. That's a real beat.

    **ALEX:** Right, and there's an interesting wrinkle in that EPS beat. $0.08 came from genuinely strong operational execution, $0.03 from foreign exchange, but $0.15 — more than half — came from tariff refunds that got recovered in the quarter.

    **JORDAN:** Yeah, that tariff refund piece is worth sitting with for a second. Management said they received approvals on the vast majority of their total potential refund claims this quarter. That added about $60 million to adjusted operating income — roughly 50 basis points of margin. But here's what I liked: they didn't just drop it straight to the bottom line. They reinvested a chunk of it into AI deployment, capacity scale-up in Pharma Services, and employee investments.

    **ALEX:** Which tells you management is thinking medium-term, not just trying to make this quarter look good.

    **JORDAN:** Exactly. It's a one-time windfall, and they treated it like one — put it to work rather than just banking it.

    **ALEX:** Let's talk end markets, because this is really the heart of the story. Pharma and biotech — their biggest and most important market — grew high single digits, led by Pharma Services and the research and safety channel. Academic and government was flat, which was expected. Industrial and applied grew high single digits, driven by electron microscopy and semiconductor demand. And diagnostics and healthcare grew low single digits.

    **JORDAN:** The pharma and biotech story is the one analysts kept circling back to in the Q&A. CEO Marc Casper talked about this almost like a staged recovery — first you saw clinical trial authorizations pick up, then lab-based research activity in biotech, and now they're expecting the high-end reagents business to be the next leg of that recovery over the next couple of quarters.

    **ALEX:** It's basically a domino effect working through the biotech funding recovery.

    **JORDAN:** And geographically, Asia Pacific — including China — grew low double digits. That's notable. China's been a wildcard for a lot of life sciences companies, and Thermo's seeing real strength there.

    **ALEX:** Now let's talk strategy, because there were some real moves this quarter. The Clario acquisition — that's the clinical research technology business — integration is going smoothly, and management's already talking about revenue synergies building.

    **JORDAN:** They also hit the one-year anniversary of the filtration and separation business acquisition, which they said strengthened their bioproduction capabilities. And on the flip side, they completed the divestiture of the microbiology business — which actually dragged reported revenue down about 1 point, but it's part of streamlining the portfolio toward higher-growth areas.

    **ALEX:** Classic port

    This episode includes AI-generated content.
    Mostra di più Mostra meno
    7 min
  • Thermo Fisher Scientific Q2 2026 Earnings Analysis

    Thermo Fisher Scientific Q2 2026 Earnings Analysis
    Jul 23 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **Beta Finch: Thermo Fisher Scientific (TMO) Q2 2026 Earnings Breakdown**

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Thermo Fisher Scientific's second quarter 2026 results, and Jordan, this is a genuinely strong print to sink our teeth into.

    JORDAN: Before we get into it, quick disclaimer for everyone listening. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    ALEX: Right, with that out of the way, let's talk numbers. Thermo Fisher posted revenue of $11.99 billion, up 10% year-over-year. Adjusted operating income jumped 15% to $2.73 billion, and adjusted EPS grew 13% to $6.03 a share.

    JORDAN: And what jumps out to me is that this wasn't a "beat on cost-cutting" quarter — this was a genuine top-line story. Organic revenue growth came in at 5%, which management explicitly said was about 2 points ahead of their own prior guidance. Margins expanded too — adjusted operating margin hit 22.8%, up 90 basis points. That's the kind of quarter where basically everything worked at once.

    ALEX: Let's break down where that growth came from. All four end markets grew mid-single-digits or better. Pharma and biotech — their biggest bucket at roughly 60% of revenue — grew mid-single digits, led by bioproduction and clinical research. Industrial and applied also grew mid-single digits, diagnostics and healthcare grew mid-single digits, and even academic and government, which has been the soft spot for a while, returned to growth, albeit low single digits.

    JORDAN: That academic and government comeback is worth sitting with for a second. CEO Marc Casper was careful not to declare victory there — he said they want to see it "more broad-based" before calling it a real trend. But the U.S. turned slightly positive, Europe was actually quite strong, and interestingly China stayed muted in that segment specifically. So it's a cautious green shoot, not a full recovery.

    ALEX: Speaking of China — it's about 7.5% of total revenue and grew low single digits, which is its first return to growth in a while. Casper credited that to pharma/biotech and industrial and applied demand, while academic spending there remains flat. He was clear it's not yet accretive to overall company growth, but the trajectory is improving.

    JORDAN: Now let's talk capital moves, because there's a lot going on here. Thermo Fisher closed the Clario acquisition in late March — that's digital clinical trial endpoint data — and it had a strong first full quarter of ownership. They also closed the filtration and separation business, formerly part of 3M/Solventum, which is showing strong demand and they're actually adding capacity.

    ALEX: And on the flip side, they're divesting their microbiology business, expected to close in Q3. That business did about $645 million in revenue in 2025. They used the anticipated proceeds to fund a $1 billion share buyback in the quarter — so essentially pre-funding the repurchase ahead of the deal closing.

    JORDAN: That divestiture does create some near-term drag, worth flagging for anyone modeling this out — management said it reduces 2026 revenue by about $200 million net of retained channel sales, and dings adjusted EPS by about $0.05 this year, growing to roughly $0.15 dilutive in the first full year after close.

    ALEX: Which makes the guidance raise even more impressive, because it absorbs that headwind and still goes up. New revenue guidance is $47.4 to $48.1 billion, representing 6-8% reported growth. Organic growth guidance moved to "about 4%" for the full year — they kept the 3-4% range but said they now expect to land at the top of it. Adjusted EPS guidance rose to $24.93 to $2

    This episode includes AI-generated content.
    Mostra di più Mostra meno
    8 min
  • Thermo Fisher Scientific Q1 2026 Earnings Analysis

    Thermo Fisher Scientific Q1 2026 Earnings Analysis
    Apr 24 2026
    **BETA FINCH PODCAST SCRIPT**

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that matter. I'm Alex.

    JORDAN: And I'm Jordan. Today we're diving into Thermo Fisher Scientific's Q1 2026 earnings, and let me tell you, this one's got some interesting moving parts.

    ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Absolutely. So Alex, TMO just reported their first quarter results, and on the surface, it looks like a pretty solid performance. What caught your attention first?

    ALEX: Well, the headline numbers are decent but not spectacular. Revenue grew 6% to $11.01 billion, and adjusted EPS came in at $5.44, also up 6%. But here's the kicker - they actually beat their own guidance by 14 cents per share on the earnings side.

    JORDAN: That's a nice beat. And they're raising full-year guidance too, right? New revenue range of $47.3 to $48.1 billion, up from the previous $46.3 to $47.2 billion range.

    ALEX: Exactly. And on earnings, they're now expecting $24.64 to $25.12 per share, up from their original $24.22 to $24.80 guide. That represents 8% to 10% growth for the year. But Jordan, there's a big asterisk here - a lot of this guidance raise comes from their massive Clario acquisition.

    JORDAN: Right, the $9 billion elephant in the room. They closed that deal in late March. Clario is a digital endpoint data solutions company that complements their clinical research business. Even though it was only in the results for a few days, it contributed $30 million in revenue and a penny per share to Q1.

    ALEX: And CEO Marc Casper was pretty excited about it on the call. He kept talking about how it enhances their "trusted partner status" with pharma and biotech customers. The integration seems to be going smoothly, and customers are apparently enthusiastic about combining Thermo's capabilities with Clario's digital endpoints technology.

    JORDAN: Speaking of pharma and biotech, that was actually their strongest end market in the quarter with mid-single digit growth. Casper highlighted strength in bioproduction and clinical research. But let's talk about the headwinds they're facing.

    ALEX: Yeah, this is where it gets interesting. They had some real operational challenges. First, they had one less selling day compared to last year, which dinged organic growth by about a percentage point. Then there was revenue phasing in pharma services - another roughly one-point headwind.

    JORDAN: So if you normalize for those factors, their 1% organic growth in Q1 would have been closer to 3%. And that's exactly what they're guiding for in Q2. The concern from analysts on the call was about this acceleration they need in the back half of the year to hit their full-year 3-4% organic growth target.

    ALEX: Casper seemed pretty confident though. He said the markets are playing out exactly as expected, and the ramp isn't really assuming any change in underlying market conditions. It's more about these timing issues and comparisons normalizing.

    JORDAN: Let's break down the segments because there were some real divergences. Life Sciences Solutions was the star with 13% reported growth, though only 1% organic. That was driven by their bioproduction business having "another quarter of excellent organic growth," as CFO Stephen Williamson put it.

    ALEX: Meanwhile, Analytical Instruments was flat on revenue with organic declining 2%. This is the ongoing story we've been hearing across the industry - weak academic and government spending, especially in the US and China. Margins in that segment got hit hard, down 250 basis points to 20.7%.

    JORDAN: Ouch. And a lot of that margin pressure was from tariffs and foreign exchange headwinds. Williamson quantified the tariff

    This episode includes AI-generated content.
    Mostra di più Mostra meno
    9 min
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione